BioStem Life Sciences, a subsidiary of BioStem Technologies, will add an R&D laboratory to its Florida, US, facility, supporting the company’s contract development and manufacturing organization (CDMO) business.
BioStem is specialized in the area of regenerative therapies, particularly in the use of perinatal tissue-based allografts. The company noted that in the first quarter of 2020, it had onboard four new projects in this space.
The lab will become part of the overall 6,100-square-foot manufacturing space, with the addition providing capacity for tech transfer and process development activities for contract manufacturing, said the company’s VP of operations and business development, Ken Warrington.
He added that the expansion is part of the company’s ‘aggressive move’ to provide contract R&D and manufacturing services.
The company currently offers contract manufacturing of finished product, cell line development and characterization, and cell banking services.
BioStem is able to manufacture plasmid DNA, cell therapeutics, viral vectors, vaccines, and recombinant proteins.
BioStem Life Sciences was formed in August 2018, after BioStem Technologies decided to launch its amnion division as a standalone business.
